Improving animal models for nervous system disorders

Genes, Brain and Behavior

Volumn 11, Issue 6, 2012, Pages 753-756

  Brown, R E ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

Author keywords

Animal models; Drug development; Nervous system disorders; Preclinical; Translational medicine

Indexed keywords

NATALIZUMAB;

ADDICTION; ALLERGIC ENCEPHALOMYELITIS; ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL MODEL; ARTICLE; BASIC RESEARCH; BEHAVIOR; BRAIN; CLINICAL RESEARCH; DEPRESSION; EPIGENETICS; GENE; GENOTYPE; HUMAN; MULTIPLE SCLEROSIS; NERVE DEGENERATION; NEUROLOGIC DISEASE; NONHUMAN; PAIN; PARKINSON DISEASE; PHENOTYPE; PREPULSE INHIBITION; PRIORITY JOURNAL; SCHIZOPHRENIA; STANDARDIZATION; STROKE; TRANSLATIONAL RESEARCH;

ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; NERVOUS SYSTEM DISEASES; TRANSLATIONAL MEDICAL RESEARCH;

ANIMALIA;

EID: 84864116971     PISSN: 16011848     EISSN: 1601183X     Source Type: Journal    
DOI: 10.1111/j.1601-183X.2012.00808.x     Document Type: Article

References (61)

1. August, S.M., Kiwanuka, J.N., McMahon, R.P. & Gold, J.M. (2012) The MATRICS Consensus Cognitive Battery (MCCB): clinical and cognitive correlates. Schizophr Res 134, 76-82.
2. Beckers, J., Wurst, W. & de Angelis, M.H. (2009) Towards better mouse models: enhanced genotypes, systematic phenotyping and envirotype modelling. Nat Rev Genet 10, 371-380.
3. van den Buuse, M. (2010) Modeling the positive symptoms of schizophrenia in genetically modified mice: pharmacology and methodology aspects. Schizophr Bull 36, 246-270.
4. Bussey, T.J., Padain, T.L., Skillings, E.A., Winters, B.D., Morton, A.J. & Saksida, L.M. (2008) The touchscreen cognitive testing method for rodents: how to get the best out of your rat. Learn Mem 15, 516-523.
5. de Calignon, A., Polydoro, M., Suárez-Calvet, M., William, C., Adamowicz, D.H., Kopeikina, K.J., Pitstick, R., Sahara, N., Ashe, K.H., Carlson, G.A., Spires-Jones, T.L. & Hyman, B.T. (2012) Propagation of tau pathology in a model of early Alzheimer's disease. Neuron 73, 685-697.
6. Chin, J. (2011) Selecting a mouse model of Alzheimer's disease. Methods Mol Biol 670, 169-189.
7. Cissé, M., Halabisky, B., Harris, J., Devidze, N., Dubal, D.B., Sun, B., Orr, A., Lotz, G., Kim, D.H., Hamto, P., Ho, K., Yu, G.Q. & Mucke, L. (2011) Reversing EphB2 depletion rescues cognitive functions in Alzheimer model. Nature 469, 47-52.
8. Clozel, M. (2011) Between confidentiality and scientific exchange: the place of publication in drug discovery and pharmaceutical research. Sci Transl Med 3, 67cm2.
9. Costenbader, K.H., Gay, S., Riquelme, M.E., Iaccarino, L. & Doria, A. (2012) Genes, epigenetic regulation and environmental factors: which is the most relevant in developing autoimmune diseases? Autoimmun Rev 11, 604-609.
10. Crabbe, J.C., Wahlsten, D. & Dudek, B.C. (1999) Genetics of mouse behavior: interactions with laboratory environment. Science 284, 1670-1672.
11. Croxford, A.L., Kurschus, F.C. & Waisman, A. (2011) Mouse models for multiple sclerosis: historical facts and future implications. Biochim Biophys Acta 1812, 177-183.
12. Crusio, W.E., Goldowitz, D., Holmes, A. & Wolfer, D. (2009) Standards for the publication of mouse mutant studies. Genes Brain Behav 8, 1-4.
13. Daniilidou, M., Koutroumani, M. & Tsolaki, M. (2011) Epigenetic mechanisms in Alzheimer's disease. Curr Med Chem 18, 1751-1756.
14. Dawson, G.R., Craig, K.J. & Dourish, C.T. (2011) Validation of experimental medicine methods in psychiatry: the P1vital approach and experience. Biochem Pharmacol 81, 1435-1441.
15. Day, J.J. & Sweatt, J.D. (2011) Epigenetic mechanisms in cognition. Neuron 70, 813-829.
16. deIpolyi, A.R., Rankin, K.P., Mucke, L., Miller, B.L. & Gorno-Tempini, M.L. (2007) Spatial cognition and the human navigation network in AD and MCI. Neurology 69, 986-997.
17. Denk, F. & McMahon, S.B. (2012) Chronic pain: emerging evidence for the involvement of epigenetics. Neuron 73, 435-444.
18. Dirnagl, U. & Lauritzen, M. (2011) Improving the quality of biomedical research: Guidelines for reporting experiments involving animals. J Cereb Blood Flow Metab 31, 989-990.
19. Fuchs, H., Gailus-Durner, V., Adler, T. et al. (2011) Mouse phenotyping. Methods 53, 120-135.
20. Gallagher, M., Bakker, A., Yassa, M.A. & Stark, C.E. (2010) Bridging neurocognitive aging and disease modification: targeting functional mechanisms of memory impairment. Curr Alzheimer Res 7, 197-199.
21. Gavin, D.P. & Sharma, R.P. (2010) Histone modifications, DNA methylation, and schizophrenia. Neurosci Biobehav Rev 34, 882-888.
22. Geerts, H. (2011) Mechanistic disease modeling as a useful tool for improving CNS drug research and development. Drug Dev Res 72, 66-73.
23. Gilmour, G., Dix, S., Fellini, L., Gastambide, F., Plath, N., Steckler, T., Talpos, J. & Tricklebank, M. (2012) NMDA receptors, cognition and schizophrenia - testing the validity of the NMDA receptor hypofunction hypothesis. Neuropharmacology 62, 1401-1412.
24. Habibi, E., Masoudi-Nejad, A., Abdolmaleky, H.M. & Haggarty, S.J. (2011) Emerging roles of epigenetic mechanisms in Parkinson's disease. Funct Integr Genomics 11, 523-537.
25. Hamm, C.A. & Costa, F.F. (2011) The impact of epigenomics on future drug design and new therapies. Drug Discov Today 216, 626-635.
26. Huang, Y. & Mucke, L. (2012) Alzheimer mechanisms and therapeutic strategies. Cell 148, 1204-1222.
27. Kafkafi, N., Benjamini, Y., Sakov, A., Elmer, G.I. & Golani, I. (2005) Genotype-environment interactions in mouse behavior: a way out of the problem. Proc Natl Acad Sci U S A 102, 4619-4624.
28. Kim, J., Bordiuk, O.L. & Ferrante, R.J. (2011) Experimental models of HD and reflection on therapeutic strategies. Int Rev Neurobiol 298, 419-481.
29. Koh, M.T., Haberman, R.P., Foti, S., McCown, T.J. & Gallagher, M. (2010) Treatment strategies targeting excess hippocampal activity benefit aged rats with cognitive impairment. Neuropsychopharmacology 35, 1016-1025.
30. Koychev, I., McMullen, K., Lees, J., Dadhiwala, R., Grayson, L., Perry, C., Schmechtig, A., Walters, J., Craig, K.J., Dawson, G.R., Dourish, C.T., Ettinger, U., Wilkinson, L., Williams, S., Deakin, J.F. & Barkus, E. (2012) A validation of cognitive biomarkers for the early identification of cognitive enhancing agents in schizotypy: a three-center double-blind placebo-controlled study. Eur Neuropsychopharmacol 22, 469-481.
31. Krishnamoorthy, G., Saxena, A., Mars, L.T., Domingues, H.S., Mentele, R., Ben-Nun, A., Lassmann, H., Dornmair, K., Kurschus, F.C., Liblau, R.S. & Wekerle, H. (2009) Myelin-specific T cells also recognize neuronal autoantigen in a transgenic mouse model of multiple sclerosis. Nat Med 15, 626-632.
32. Langer-Gould, A. & Steinman, L. (2006) What went wrong in the natalizumab trials? Lancet 367, 708-710.
33. Levaux, M.N., Potvin, S., Sepehry, A.A., Sablier, J., Mendrek, A. & Stip, E. (2007) Computerized assessment of cognition in schizophrenia: promises and pitfalls of CANTAB. Eur Psychiatry 22, 104-115.
34. Lucchinetti, C.F., Popescu, B.F., Bunyan, R.F., Moll, N.M., Roemer, S.F., Lassmann, H., Brück, W., Parisi, J.E., Scheithauer, B.W., Giannini, C., Weigand, S.D., Mandrekar, J. & Ransohoff, R.M. (2011) Inflammatory cortical demyelination in early multiple sclerosis. N Engl J Med 365, 2188-2197.
35. Ludolph, A.C., Bendotti, C., Blaugrund, E., Chio, A., Greensmith, L., Loeffler, J.P., Mead, R., Niessen, H.G., Petri, S., Pradat, P.F., Robberecht, W., Ruegg, M., Schwalenstocker, B., Stiller, D., van den Berg, L., Vieira, F. & von Horsten . (2010) Guidelines for preclinical animal research in ALS/MND: A consensus meeting. Amyotroph Lateral Scler 11, 38-45.
36. Manaenko, A., Chen, H., Zhang, J.H. & Tang, J. (2011) Comparison of different preclinical models of intracerebral hemorrhage. Acta Neurochir Suppl 111, 9-14.
37. Mix, E., Meyer-Rienecker, H., Hartung, H.P. & Zettl, U.K. (2010) Animal models of multiple sclerosis - potentials and limitations. Prog Neurobiol 92, 386-404.
38. Mogil, J.S. (2009) Animal models of pain: progress and challenges. Nat Rev Neurosci 10, 283-294.
39. Moore, H. (2010) The role of rodent models in the discovery of new treatments for schizophrenia: updating our strategy. Schizophr Bull 36, 1066-1072.
40. Morgan, P., Van Der Graaf, P.H., Arrowsmith, J., Feltner, D.E., Drummond, K.S., Wegner, C.D. & Street, S.D. (2012) Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving Phase II survival. Drug Discov Today 17, 419-424.
41. Nieuwenhuis, S., Forstmann, B.U. & Wagenmakers, E.J. (2011) Erroneous analyses of interactions in neuroscience: a problem of significance. Nat Neurosci 14, 1105-1107.
42. NINDS. 2011. Improving the quality of NINDS-supported preclinical and clinical research through rigorous study design and transparent reporting, 2 pages, on line. .
43. Paul, S.M., Mytelka, D.S., Dunwiddie, C.T., Persinger, C.C., Munos, B.H., Lindborg, S.R. & Schacht, A.L. (2010) How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nat Rev Drug Discov 9, 203-214.
44. Powell, S.B., Weber, M. & Geyer, M.A. (2012) Genetic models of sensorimotor gating: relevance to neuropsychiatric disorders. Curr Top Behav Neurosci 12, 251-318.
45. Putcha, D., Brickhouse, M., O'Keefe, K., Sullivan, C., Rentz, D., Marshall, G., Dickerson, B. & Sperling, R. (2011) Hippocampal hyperactivation associated with cortical thinning in Alzheimer's disease signature regions in non-demented elderly adults. J Neurosci 31, 17680-17688.
46. Richter, S.H., Garner, J.P. & Würbel, H. (2009) Environmental standardization: cure or cause of poor reproducibility in animal experiments? Nat Methods 6, 257-261.
47. Schellinck, H.M., Cyr, D.P. & Brown, R.E. (2010). How many ways can mouse behavioral experiments go wrong? Confounding variables in mouse models of neurodegenerative diseases and how to control them. Adv Study Behav 41, 255-366.
48. Shineman, D.W., Basi, G.S., Bizon, J.L., Colton, C.A., Greenberg, B.D., Hollister, B.A., Lincecum, J., Leblanc, G.G., Lee, L.B., Luo, F., Morgan, D., Morse, I., Refolo, L.M., Riddell, D.R., Scearce-Levie, K., Sweeney, P., Yrjanheikki, J. & Fillit, H.M. (2011) Accelerating drug discovery for Alzheimer's disease: best practices for preclinical animal studies. Alzheimers Res Ther 3, 28.
49. Sora, I., Li, B., Igari, M., Hall, F.S. & Ikeda, K. (2010) Transgenic mice in the study of drug addiction and the effects of psychostimulant drugs. Ann N Y Acad Sci 1187, 218-246.
50. Sorger, P.K. & Allerheiligen, S.R.B. (2011) Quantitative and systems pharmacology in the post-genomic era: New approaches to discovering drugs and understanding therapeutic mechanisms. An NIH white paper by the QSP workshop group-October 2011 . .
51. Steinman, L. (2005) Blocking adhesion molecules as therapy for multiple sclerosis: natalizumab. Nat Rev Drug Discov 4, 510-518.
52. Steinman, L., Merrill, J.T., McInnes, I.B. & Peakman, M. (2012) Optimization of current and future therapy for autoimmune diseases. Nat Med 18, 59-65.
53. Stokes, W.S. (2011) Best practices for the use of animals in toxicological research and testing. Ann N Y Acad Sci 1245, 17-20.
54. Swerdlow, N.R., van Bergeijk, D.P., Bergsma, F., Weber, E. & Talledo, J. (2009) The effects of memantine on prepulse inhibition. Neuropsychopharmacology 34, 1854-1864.
55. Swinney, D.C. & Anthony, J. (2011) How were new medicines discovered? Nat Rev Drug Discov 10, 507-519.
56. Tricklebank, M.D. & Garner, J.P. (2012) The possibilities of animal models for psychiatric disorders. In Rankovic, Z., Hargreaves, R. & Bingham, M. (eds), Drug Discovery and Medicinal Chemistry for Psychiatric Disorders. Chap. 18. Royal Society of Chemistry, Cambridge, UK.
57. Wang, S.J., Hung, H.M. & O'Neill, R. (2011) Adaptive design clinical trials and trial logistics models in CNS drug development. Eur Neuropsychopharmacol 21, 159-166.
58. Wong, C.C., Mill, J. & Fernandes, C. (2011) Drugs and addiction: an introduction to epigenetics. Addiction 106, 480-489.
59. Yassa, M.A. & Stark, C.E. (2011) Pattern separation in the hippocampus. Trends Neurosci 34, 515-525.
60. Young, N.S., Ioannidis, J.P. & Al-Ubaydli, O. (2008) Why current publication practices may distort science. PLoS Med 5, e201.
61. Young, J.W., Powell, S.B., Risbrough, V., Marston, H.M. & Geyer, M.A. (2009) Using the MATRICS to guide development of a preclinical cognitive test battery for research in schizophrenia. Pharmacol Ther 122, 150-202.